EUVIMEDEUVIMED entdecken
Klinische Studie

Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions

Gabriel P E Silveira, Luciana F Portela, Leticia B Saavedra, Filipe P Costa, Douglas P Pinto, Fernanda M Carneiro, Juliana Almeida-Silva, Gilberto M Sperandio da Silva, Mauro F F Mediano, Vitoria B Cattani, Marcel S B Quintana, Paula S Silva und 8 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf416 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Gabriel P E Silveira und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics Service (SEFAR), Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Drug-Related Side Effects and Adverse Reactions, Trypanocidal Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico, INOVA Fiocruz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The knowledge about benznidazole pharmacokinetics (PK) in patients with chronic Chagas disease (CD) is limited.

Objective

To evaluate the benznidazole PK parameters in patients with chronic CD, stratified by age, sex, and adverse drug reactions (ADRs) occurrence.

Methods

Single-centre, open-label, clinical trial that included adult patients with chronic CD who received benznidazole 300 mg/day for 60–80 days. Blood samples were collected on Days 1, 7, 15, 30, and 60 of treatment. Benznidazole was quantified by HPLC-MS/MS and PK analysis used non-compartmental analysis.

Results

Twenty-nine participants (16 females; 55.2%) were included. Five (17.2%) participants interrupted the treatment definitely due to ADRs. PK parameters after a single benznidazole dose were as follows: Cmax = 2.48(0.53) µg/mL, AUC0–6 = 10.80(2.59) h*µg/mL, and Tmax = 2.7(1.3) h. The steady-state PK parameters on Day 15 were as follows: Cmax,ss = 7.86(2.06) µg/mL, AUC0–6,ss = 42.05(10.87) h*µg/mL, and Tmax,ss = 2.3 (1.2 h). Tmax was longer among those ≥60 years old (P = 0.045), and Cmax (P = 0.0004) and AUC0–6 (P = 0.003) were higher in females, but PK parameters normalized by weight were similar between sexes. The most frequent ADRs were skin reactions (44.8%), gastrointestinal (37.9%), haematological (20.7%), and neurological (27.6%). Sex was associated with gastrointestinal ADRs, while weight was associated with skin reactions. Higher benznidazole plasma levels on Days 1, 7, and 15 of treatment were associated with skin reactions even adjusting for age and sex.

Conclusions

Benznidazole PK presented little variation according to sex and age, but differences in sex appeared linked to females lower weight. Higher benznidazole plasma levels were associated with skin reactions, indicating a potential dose-dependent relationship of this ADR.

Trial registration

This study was registered on the Brazilian Clinical Trials Database—REBEC (RBR-5vg8p36). Registered on 11 August 2021. https://ensaiosclinicos.gov.br/rg/RBR-5vg8p36.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesChagas DiseaseDrug-Related Side Effects and Adverse ReactionsTrypanocidal AgentsHumansFemaleMaleMiddle AgedAdultAgedYoung AdultTandem Mass SpectrometryChronic DiseaseChromatography, High Pressure Liquid

Substanzen

NitroimidazolesbenzonidazoleTrypanocidal Agents

Autor:innen und Institutionen

  • Pharmacokinetics Service (SEFAR), Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.
  • Sérgio Arouca National School of Public Health, Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.
  • Laboratory of Clinical Research on Chagas Disease, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.
  • Innovations in Therapies, Education and Bioproducts Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.
  • Laboratory of Clinical Epidemiology, Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.
  • Experimental Pharmacotechnics Laboratory, Department of Galenic Innovation, Institute of Drug Technology-Farmanguinhos, Oswaldo Cruz Foundation, Av Brasil, Rio de Janeiro, RJ 4365, Brazil.

ORCID-Profile: Roberto M Saraiva

Förderung

  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • INOVA Fiocruz

Zitieren

APA

Silveira, G. P. E., Portela, L. F., Saavedra, L. B., Costa, F. P., Pinto, D. P., Carneiro, F. M., Almeida-Silva, J., da Silva, G. M. S., Mediano, M. F. F., Cattani, V. B., Quintana, M. S. B., Silva, P. S., Sangenis, L. H. C., Costa, A. R., Hasslocher-Moreno, A. M., Viçosa, A. L., Perez, S. A. C., Vannier-Santos, M. A., Estrela, R., & Saraiva, R. M. (2026). Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf416

Vancouver

Silveira GPE, Portela LF, Saavedra LB, Costa FP, Pinto DP, Carneiro FM, et al. Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf416

BibTeX
@article{Silveira2026,
  author = {Silveira, Gabriel P E and Portela, Luciana F and Saavedra, Leticia B and Costa, Filipe P and Pinto, Douglas P and Carneiro, Fernanda M and Almeida-Silva, Juliana and da Silva, Gilberto M Sperandio and Mediano, Mauro F F and Cattani, Vitoria B and Quintana, Marcel S B and Silva, Paula S and Sangenis, Luiz Henrique C and Costa, Andréa R and Hasslocher-Moreno, Alejando M and Viçosa, Alessandra L and Perez, Sandra Aurora C and Vannier-Santos, Marcos André and Estrela, Rita and Saraiva, Roberto M},
  title = {Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf416}
}
Kostenlos starten →